CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04−0.09 (-4.23%)
Close on Nov 12, 2026Market cap $444.52MP/E –Yield –
CytomX Therapeutics statistics
82 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Mar 15, 2027 (estimated, before the open)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 12, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 1.57
- 2.29
Enterprise valuationIndustry
- EV / Sales
- 6.88
- 2.60
Share statisticsIndustry
- Shares Change (YoY)
- 67.2%
- 10.9%
- Float
- 215M
- 49M
- Shares Held by Insiders
- 1.51%
- 12.1%
- Shares Held by Institutions
- 97.9%
- 56.4%
Short sellingIndustry
- Short Interest
- 45M
- –
- Short Interest Change
- 5.74%
- -0.76%
- Short % of Float
- 21.1%
- 9.04%
- Short % of Shares Outstanding
- 20.8%
- 6.30%
- Days to Cover
- 11.99
- 5.13
Stock price statisticsIndustry
- 52-Week High
- $8.21
- –
- 52-Week Low
- $1.90
- –
- 20-Day Moving Average
- $2.25
- –
- 50-Day Moving Average
- $2.60
- –
- 200-Day Moving Average
- $3.73
- –
- Average True Range (14)
- $0.18
- –
- Price Change (1 Week)
- -4.67%
- 1.51%
- Price Change (1 Month)
- -8.52%
- -2.35%
- Price Change (3 Months)
- -39.3%
- -21.1%
- Price Change (6 Months)
- -46.0%
- -22.6%
- Price Change (YTD)
- -52.1%
- -22.6%
- Price Change (1 Year)
- -50.2%
- -20.7%
- Price Change (3 Years)
- 65.9%
- -27.4%
- Price Change (5 Years)
- -70.9%
- -77.3%
- Price Change (10 Years)
- -81.8%
- -62.7%
- Average Volume (10 Days)
- 7M
- –
- Average Volume (20 Days)
- 5M
- –
- Average Volume (90 Days)
- 4M
- –
- Relative Volume
- 0.83
- 0.79
- Relative Strength Index (14)
- 39.3
- 44.7
- Volatility (1 Year)
- 85.6%
- 80.4%
- Beta (5 Years)
- 1.58
- 1.07
MarginsIndustry
- Pretax Margin
- -607.3%
- -11.8%
- EBITDA Margin
- -676.5%
- -27.7%
- FCF Margin
- -363.6%
- -9.20%
Returns on capitalIndustry
- Return on Equity (ROE)
- -43.6%
- -51.2%
- Return on Assets (ROA)
- -32.7%
- -40.6%
- Return on Capital Employed (ROCE)
- -29.7%
- -38.0%
Financial positionIndustry
- Current Ratio
- 7.82
- 3.30
- Quick Ratio
- 7.65
- 2.42
GrowthIndustry
- Revenue Growth (YoY)
- -87.7%
- 7.01%
- Net Income Growth (YoY)
- -404.9%
- -14.4%
- EPS Growth (YoY)
- -215.0%
- -11.7%
- Revenue Growth (3Y CAGR)
- 12.8%
- 2.25%
- Revenue Growth (5Y CAGR)
- 2.18%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.05
- 0.40
- Revenue Per Employee
- $203.29K
- $429.29K
- Profits Per Employee
- -$1.24M
- -$683.67K
- Employee Count
- 69
- 75
- WACC
- 12.9%
- 10.1%
Income statement (TTM)Industry
- Pretax Income
- -$85.19M
- -$13.23M
Balance sheetIndustry
- Net Cash (Debt)
- $347.98M
- $17.46M
- Net Cash Per Share
- $1.60
- $0.72
- Equity (Book Value)
- $284.89M
- $53.27M
- Book Value Per Share
- $1.31
- $1.50
- Tangible Book Value
- $283.94M
- $26.82M
- Working Capital
- $310.52M
- $79.47M
Cash flow (TTM)Industry
- Capital Expenditures
- -$790.00K
- -$944.00K
- FCF Per Share
- -$0.23
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -19.2%
- -20.8%
- FCF Yield
- -11.5%
- -9.58%
- Buyback Yield
- -55.0%
- -0.73%
- Shareholder Yield
- -55.0%
- 0.00%
Taxes and interestIndustry
- Income Tax
- $234.00K
- $74.00K
Scores and fair valueIndustry
- Altman Z-Score
- 0.58
- 0.30
- Piotroski F-Score
- 2
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CTMX | S&P 500 | Difference | CTMX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -15.7% | -2.7% | −13.0 pts | ||
| 3 months | -41.5% | -1.7% | −39.8 pts | ||
| Year to date | -52.1% | +11.9% | −64.0 pts | ||
| 1 year | -51.8% | +12.0% | −63.8 pts | ||
| 3 years | +74.4% | +78.2% | −3.8 pts | +20.4% | +21.2% |
| 5 years | -70.9% | +73.2% | −144.2 pts | -21.9% | +11.6% |
| 10 years | -81.8% | +309.6% | −391.5 pts | -15.7% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
45M CTMX shares were sold short on Oct 30, 2026, up 5.7% from the previous report, or 21.08% of the shares available to trade. At recent volumes it would take 12.0 days to buy them back. Over the last 20 sessions, 48.3% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 45,246,966 | +5.7% | 3,772,440 | 12.0 |
| Oct 15, 2026 | 42,790,446 | +4.8% | 3,106,047 | 13.8 |
| Sep 30, 2026 | 40,813,393 | +5.6% | 4,704,960 | 8.7 |
| Sep 15, 2026 | 38,639,220 | +15.3% | 4,157,686 | 9.3 |
| Aug 31, 2026 | 33,512,293 | -3.2% | 2,837,694 | 11.8 |
| Aug 14, 2026 | 34,619,999 | -1.4% | 2,173,486 | 15.9 |
| Jul 31, 2026 | 35,110,952 | -12.9% | 2,981,073 | 11.8 |
| Jul 15, 2026 | 40,322,256 | +13.4% | 3,885,595 | 10.4 |
| Jun 30, 2026 | 35,567,462 | +16.2% | 8,231,326 | 4.3 |
| Jun 15, 2026 | 30,605,562 | +6.6% | 3,536,758 | 8.7 |
| May 29, 2026 | 28,719,341 | -7.8% | 3,085,637 | 9.3 |
| May 15, 2026 | 31,133,767 | +4.7% | 3,017,256 | 10.3 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?